{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:16:41Z","timestamp":1790727401035,"version":"4.1.0"},"reference-count":97,"publisher":"Frontiers Media SA","content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2017.00093","type":"journal-article","created":{"date-parts":[[2017,5,12]],"date-time":"2017-05-12T03:45:37Z","timestamp":1494560737000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers"],"prefix":"10.3389","volume":"7","author":[{"given":"Assia L.","family":"Angelova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathias","family":"Witzens-Harig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel S.","family":"Galabov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Rommelaere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2017,5,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1099\/0022-1317-79-11-2871","article-title":"One hundred years of animal virology","volume":"79","author":"Rott","year":"1998","journal-title":"J Gen Virol"},{"key":"B2","first-page":"27","article-title":"The etiology of yellow fever \u2013 a preliminary note","volume":"26","author":"Reed","year":"1900","journal-title":"Public Health Pap Rep"},{"key":"B3","first-page":"765","article-title":"Le passage du virus rabique \u00e0 travers les filtres","volume":"101","author":"Remlinger","year":"1903","journal-title":"Annales de L\u2019Institut Pasteur (Paris)"},{"key":"B4","first-page":"377","article-title":"\u00dcbertragung der Poliomyelitis acuta auf Affen","volume":"2","author":"Landsteiner","year":"1909","journal-title":"Zeitschrift f\u00fcr Immunit\u00e4tsforschung und Experimentelle Therapie"},{"key":"B5","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1126\/science.6189183","article-title":"Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS)","volume":"220","author":"Barre-Sinoussi","year":"1983","journal-title":"Science"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1098\/rstb.2011.0354","article-title":"Human viruses: discovery and emergence","volume":"367","author":"Woolhouse","year":"2012","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"key":"B7","first-page":"115","article-title":"Viruses and human cancer","volume":"79","author":"Liao","year":"2006","journal-title":"Yale J Biol Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/BF00195138","article-title":"Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins","volume":"73","author":"Hoppe-Seyler","year":"1995","journal-title":"J Mol Med (Berl)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.3390\/cancers6042155","article-title":"Viral carcinogenesis: factors inducing DNA damage and virus integration","volume":"6","author":"Chen","year":"2014","journal-title":"Cancers"},{"key":"B10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.bbadis.2007.12.005","article-title":"Viruses associated with human cancer","volume":"1782","author":"McLaughlin-Drubin","year":"2008","journal-title":"Biochim Biophys Acta"},{"key":"B11","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/1097-0142(195305)6:3<591::AID-CNCR2820060317>3.0.CO;2-M","article-title":"Remissions in leukemia of childhood following acute infectious disease","volume":"6","author":"Bierman","year":"1953","journal-title":"Cancer"},{"key":"B12","first-page":"26","article-title":"Observaci\u00f3n de un caso de enfermedad de Hodgkin, con regresi\u00f3n de las s\u00edtomas e infartos ganglionares, post-sarampi\u00f3n","volume":"8","author":"Hernandez","year":"1949","journal-title":"Arch Cubanos Cancer"},{"key":"B13","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S0140-6736(71)91186-X","article-title":"Hodgkin\u2019s disease: remissions after measles","volume":"1","author":"Zygiert","year":"1971","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/S0140-6736(81)92286-8","article-title":"Regression of Hodgkin\u2019s disease after measles","volume":"1","author":"Taqi","year":"1981","journal-title":"Lancet"},{"key":"B15","first-page":"473","article-title":"Studies in Hodgkin\u2019s syndrome; the association of viral hepatitis and Hodgkin\u2019s disease; a preliminary report","volume":"9","author":"Hoster","year":"1949","journal-title":"Cancer Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/S0140-6736(71)92086-1","article-title":"Regression of Burkitt\u2019s lymphoma in association with measles infection","volume":"2","author":"Bluming","year":"1971","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/nbt.2287","article-title":"Oncolytic virotherapy","volume":"30","author":"Russel","year":"2012","journal-title":"Nat Biotechnol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol Ther"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.2064","article-title":"Oncolytic viruses in cancer treatment: a review","author":"Lawler","year":"2016","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nrc3770","article-title":"Going viral with cancer immunotherapy","volume":"14","author":"Lichty","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1038\/nrmicro3140","article-title":"New viruses for cancer therapy: meeting clinical needs","volume":"12","author":"Miest","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.chom.2014.01.002","article-title":"Viruses for tumor therapy","volume":"15","author":"Bell","year":"2014","journal-title":"Cell Host Microbe"},{"key":"B23","unstructured":"FDA Approves First-of-Its-Kind Product for the Treatment of Melanoma2015"},{"key":"B24","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1002\/tera.1420030311","article-title":"Attempts to isolate H-1 virus from spontaneous human abortions: a negative report","volume":"3","author":"Neuman","year":"1970","journal-title":"Teratology"},{"key":"B26","doi-asserted-by":"publisher","first-page":"711","DOI":"10.3181\/00379727-119-30278","article-title":"H-1 virus viremia in the human","volume":"119","author":"Toolan","year":"1965","journal-title":"Proc Soc Exp Biol Med"},{"key":"B27","first-page":"297","article-title":"Intra-lesional administration of a live virus, parvovirus H1 (PVH1) in cancer patients: a feasibility study","volume":"12","author":"Le Cesne","year":"1993","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.cytogfr.2010.02.011","article-title":"Oncolytic parvoviruses as cancer therapeutics","volume":"21","author":"Rommelaere","year":"2010","journal-title":"Cytokine Growth Factor Rev"},{"key":"B29","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3389\/fbioe.2015.00055","article-title":"Tumor selectivity of oncolytic parvoviruses: from in vitro and animal models to cancer patients","volume":"3","author":"Angelova","year":"2015","journal-title":"Front Bioeng Biotechnol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.coviro.2015.03.008","article-title":"Double-faceted mechanism of parvoviral oncosuppression","volume":"13","author":"Geletneky","year":"2015","journal-title":"Curr Opin Virol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1097\/SLA.0b013e31821fd334","article-title":"Pancreatic cancer surgery in the new millennium: better prediction of outcome","volume":"254","author":"Hartwig","year":"2011","journal-title":"Ann Surg"},{"key":"B32","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1158\/1078-0432.CCR-08-1088","article-title":"Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV","volume":"15","author":"Angelova","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","first-page":"5263","DOI":"10.1128\/JVI.03688-13","article-title":"Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer","volume":"88","author":"Angelova","year":"2014","journal-title":"J Virol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2914","DOI":"10.1002\/ijc.24992","article-title":"SMAD4: a predictive marker of PDAC cell permissiveness for oncolytic infection with parvovirus H-1PV","volume":"126","author":"Dempe","year":"2010","journal-title":"Int J Cancer"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.4161\/cbt.10.12.13455","article-title":"Immune cells participate in the oncosuppressive activity of parvovirus H-1PV and are activated as a result of their abortive infection with this agent","volume":"10","author":"Grekova","year":"2010","journal-title":"Cancer Biol Ther"},{"key":"B36","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1002\/ijc.25415","article-title":"Enhancement of NK cell antitumor responses using an oncolytic parvovirus","volume":"128","author":"Bhat","year":"2011","journal-title":"Int J Cancer"},{"key":"B37","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4161\/cbt.12.10.17678","article-title":"Interferon \u03b3 improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer","volume":"12","author":"Grekova","year":"2011","journal-title":"Cancer Biol Ther"},{"key":"B38","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/978-3-7091-1419-3_25","article-title":"Parvoviruses: the friendly anticancer immunomodulator","volume-title":"Molecular Vaccines","author":"Raykov","year":"2013"},{"key":"B39","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1517\/14712598.2016.1151492","article-title":"Virotherapy of digestive tumors with rodent parvovirus: overview and perspectives","volume":"16","author":"Akladios","year":"2016","journal-title":"Expert Opin Biol Ther"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.1093\/neuonc\/nor110","article-title":"Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?","volume":"13","author":"Clarke","year":"2011","journal-title":"Neuro Oncol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1002\/ijc.11626","article-title":"Parvovirus H-1 infection of human glioma cells leads to complete viral replication and efficient cell killing","volume":"109","author":"Herrero","year":"2004","journal-title":"Int J Cancer"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3390\/v8050138","article-title":"Pediatric and adult high-grade glioma stem cell culture models are permissive to lytic infection with parvovirus H-1","volume":"8","author":"Josupeit","year":"2016","journal-title":"Viruses"},{"key":"B43","doi-asserted-by":"publisher","first-page":"4186","DOI":"10.1128\/JVI.02601-06","article-title":"Cytosolic activation of cathepsins mediates parvovirus H-1-induced killing of cisplatin and TRAIL-resistant glioma cells","volume":"81","author":"Di Piazza","year":"2007","journal-title":"J Virol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"350748","DOI":"10.1155\/2010\/350748","article-title":"Improved killing of human high-grade glioma cells by combining ionizing radiation with oncolytic parvovirus H-1 infection","volume":"2010","author":"Geletneky","year":"2010","journal-title":"J Biomed Biotechnol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/neuonc\/noq023","article-title":"Regression of advanced rat and human gliomas by local or systemic treatment with oncolytic parvovirus H-1 in rat models","volume":"12","author":"Geletneky","year":"2010","journal-title":"Neuro Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"5333","DOI":"10.1158\/1078-0432.CCR-10-3124","article-title":"Regression of glioma in rat models by intranasal application of parvovirus H-1","volume":"17","author":"Kiprianova","year":"2011","journal-title":"Clin Cancer Res"},{"key":"B47","first-page":"36","article-title":"Bioavailability, biodistribution, and CNS toxicity of clinical-grade parvovirus H1 after intravenous and intracerebral injection in rats","volume":"65","author":"Geletneky","year":"2015","journal-title":"Comp Med"},{"key":"B48","first-page":"23","article-title":"Pathology, organ distribution, and immune response after single and repeated intravenous injection of rats with clinical-grade parvovirus H1","volume":"65","author":"Geletneky","year":"2015","journal-title":"Comp Med"},{"key":"B49","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/1471-2407-12-99","article-title":"Phase I\/IIa study of intratumoral\/intracerebral or intravenous\/intracerebral administration of parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol","volume":"12","author":"Geletneky","year":"2012","journal-title":"BMC Cancer"},{"key":"B50","doi-asserted-by":"publisher","first-page":"6683","DOI":"10.1128\/JVI.77.12.6683-6691.2003","article-title":"Replicating parvoviruses that target colon cancer cells","volume":"77","author":"Malerba","year":"2003","journal-title":"J Virol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2147\/OTT.S49371","article-title":"Influence of the oncolytic parvovirus H-1, CTLA-4 antibody tremelimumab and cytostatic drugs on the human immune system in a human in vitro model of colorectal cancer","volume":"6","author":"Heinrich","year":"2013","journal-title":"Onco Targets Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1038\/leu.2009.219","article-title":"Myxoma virus targets primary human leukemic stem and progenitor cells while sparing normal hematopoietic stem and progenitor cells","volume":"23","author":"Kim","year":"2009","journal-title":"Leukemia"},{"key":"B53","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.clml.2015.12.005","article-title":"Myxoma virus induces ligand independent extrinsic apoptosis in human myeloma cells","volume":"16","author":"Bartee","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B54","doi-asserted-by":"publisher","first-page":"16032","DOI":"10.1038\/mto.2016.32","article-title":"Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice","volume":"3","author":"Bartee","year":"2016","journal-title":"Mol Ther Oncolytics"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1038\/leu.2008.120","article-title":"Oncolytic virotherapy for multiple myeloma using a tumour-specific double-deleted vaccinia virus","volume":"22","author":"Deng","year":"2008","journal-title":"Leukemia"},{"key":"B56","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1089\/hum.2009.082","article-title":"Infection and killing of multiple myeloma by adenoviruses","volume":"21","author":"Senac","year":"2010","journal-title":"Hum Gene Ther"},{"key":"B57","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06550.x","article-title":"Oncolytic coxsackievirus A21 as a novel therapy for multiple myeloma","volume":"137","author":"Au","year":"2007","journal-title":"Br J Haematol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1182\/blood-2002-08-2508","article-title":"Reovirus oncolysis as a novel purguing strategy for autologous stem cell transplantation","volume":"102","author":"Thirukkumaran","year":"2003","journal-title":"Blood"},{"key":"B59","doi-asserted-by":"publisher","first-page":"4962","DOI":"10.1158\/1078-0432.CCR-11-3085","article-title":"Reovirus as a viable therapeutic option for the treatment of multiple myeloma","volume":"18","author":"Thirukkumaran","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B60","doi-asserted-by":"publisher","first-page":"413","DOI":"10.4161\/auto.22867","article-title":"Reovirus modulates autophagy during oncolysis of multiple myeloma","volume":"9","author":"Thirukkumaran","year":"2013","journal-title":"Autophagy"},{"key":"B61","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/cgt.2012.14","article-title":"Potent systemic therapy of multiple myeloma utilizing oncolytic vesicular stomatitis virus coding for interferon-beta","volume":"19","author":"Naik","year":"2012","journal-title":"Cancer Gene Ther"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1182\/blood.V98.7.2002","article-title":"Systemic therapy of myeloma xenografts by an attenuated measles virus","volume":"98","author":"Peng","year":"2001","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","article-title":"Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter","volume":"103","author":"Dingli","year":"2004","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1038\/sj.clpt.6100409","article-title":"Preclinical pharmacology and toxicity of intravenoues MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide","volume":"82","author":"Myers","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"B65","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russel","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"B66","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1089\/hum.2004.15.821","article-title":"Vesicular stomatitis virus: a potential therapeutic virus for the treatment of hematologic malignancy","volume":"15","author":"Lichty","year":"2004","journal-title":"Hum Gene Ther"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.exphem.2005.07.009","article-title":"Adenovirus infection and cytotoxicity of primary mantle cell lymphoma cells","volume":"33","author":"Medina","year":"2005","journal-title":"Exp Hematol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/sj.leu.2405034","article-title":"Enhanced antitumor activity by a selective conditionally replicating adenovirus combining with MDA-7\/interleukin-24 for B-lymphoblastic leukemia via induction of apoptosis","volume":"22","author":"Qian","year":"2008","journal-title":"Leukemia"},{"key":"B69","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.molonc.2009.07.002","article-title":"Transcription factors down-stream of Ras as molecular indicators for targeting malignancies with oncolytic herpes virus","volume":"3","author":"Esfandyari","year":"2009","journal-title":"Mol Oncol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.1182\/blood-2002-02-0503","article-title":"Reovirus therapy of lymphoid malignancies","volume":"100","author":"Allain","year":"2002","journal-title":"Blood"},{"key":"B71","doi-asserted-by":"publisher","first-page":"8487","DOI":"10.1128\/JVI.00851-08","article-title":"Targeting the apoptotic pathway with BCL-2 inhibitors sensitizes primary chronic lymphocytic leukemia cells to vesicular stomatitis virus-induced oncolysis","volume":"82","author":"Tumilasci","year":"2008","journal-title":"J Virol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"3746","DOI":"10.1182\/blood.V97.12.3746","article-title":"Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice","volume":"97","author":"Grote","year":"2001","journal-title":"Blood"},{"key":"B73","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/gt.2010.150","article-title":"CD20-targeted measles virus shows high oncolytic specificity in clinical samples from lymphoma patients independent of prior rituximab therapy","volume":"18","author":"Yaiw","year":"2011","journal-title":"Gene Ther"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1038\/mt.2011.44","article-title":"Differential cytopathology and kinetics of measles oncolysis in two primary B-cell malignancies provides mechanistic insights","volume":"19","author":"Patel","year":"2011","journal-title":"Mol Ther"},{"key":"B75","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1038\/mt.2013.171","article-title":"Measles virus entry through the signaling lymphocyte activation molecule governs efficacy of mantle cell lymphoma radiovirotherapy","volume":"21","author":"Miest","year":"2013","journal-title":"Mol Ther"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1182\/blood-2013-09-528851","article-title":"Human mesenchymal stromal cells deliver systemic oncolytic measles virus to treat acute lymphoblastic leukemia in the presence of humoral immunity","volume":"123","author":"Castleton","year":"2014","journal-title":"Blood"},{"key":"B77","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1128\/JVI.63.5.2152-2158.1989","article-title":"Transformation of human cells by oncogenic viruses supports permissiveness for parvovirus H-1 propagation","volume":"63","author":"Faisst","year":"1989","journal-title":"J Virol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/0168-1702(90)90024-6","article-title":"Persistence of parvovirus H-1 DNA in human B- and T-lymphoma cells","volume":"16","author":"Faisst","year":"1990","journal-title":"Virus Res"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1038\/mt.2009.78","article-title":"Oncolytic rat rarvovirus H-1PV, a candidate for the treatment of human lymphoma: in vitro and in vivo studies","volume":"17","author":"Angelova","year":"2009","journal-title":"Mol Ther"},{"key":"B80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s12185-016-2031-1","article-title":"Gene and virotherapy for hematological malignancies","volume":"104","author":"Domingo-Musibay","year":"2016","journal-title":"Int J Hematol"},{"key":"B81","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"B82","first-page":"148","article-title":"Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P T"},{"key":"B83","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1053\/seminhematol.2013.06.007","article-title":"A 50-year journey to cure childhood acute lymphoblastic leukemia","volume":"50","author":"Pui","year":"2013","journal-title":"Semin Hematol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1182\/blood-2014-10-551895","article-title":"How I treat T-cell acute lymphoblastic leukemia in adults","volume":"126","author":"Litzow","year":"2015","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1097\/CCO.0000000000000009","article-title":"Targeted therapy with monoclonal antibodies in acute lymphoblastic leukemia","volume":"25","author":"Hoelzer","year":"2013","journal-title":"Curr Opin Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/2040620715594736","article-title":"Adoptive T-cell therapies for refractory\/relapsed leukemia and lymphoma: current strategies and recent advances","volume":"6","author":"McLaughlin","year":"2015","journal-title":"Ther Adv Hematol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1182\/blood-2004-11-4558","article-title":"Oncolytic measles virus in cutaneous T-cell lymphoma mounts antitumor immune responses in vivo and targets interferon-resistant tumor cells","volume":"106","author":"Heinzerling","year":"2005","journal-title":"Blood"},{"key":"B88","first-page":"952","article-title":"Can parvovirus B19 infection be naturally oncolytic: clinical findings raise such a possibility in leukaemic children","volume":"139","author":"Kishore","year":"2014","journal-title":"Indian J Med Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/j.1365-2141.2011.09013.x","article-title":"Epidemiology: clues to the pathogenesis of Burkitt lymphoma","volume":"156","author":"Magrath","year":"2012","journal-title":"Br J Haematol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"5349","DOI":"10.2147\/OTT.S107957","article-title":"ALDH1A1 induces resistance to CHOP in diffuse large B-cell lymphoma through activation of the JAK2\/STAT3 pathway","volume":"9","author":"Jiang","year":"2016","journal-title":"Onco Targets Ther"},{"key":"B91","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.clcl.2012.06.010","article-title":"Age, race, sex, stage, and incidence of cutaneous lymphoma","volume":"12","author":"Wilson","year":"2012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B92","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1080\/10428190802136368","article-title":"Primary cutaneous lymphomas: a population-based descriptive study of 71 consecutive cases diagnosed between 1980 and 2003","volume":"49","author":"Riou-Gotta","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"B93","doi-asserted-by":"publisher","first-page":"5410","DOI":"10.1200\/JCO.2008.21.6150","article-title":"Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma","volume":"27","author":"Piekarz","year":"2009","journal-title":"J Clin Oncol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"471","DOI":"10.4155\/fmc.12.6","article-title":"HDAC inhibitors for the treatment of cutaneous T-cell lymphoma","volume":"4","author":"Rangwala","year":"2012","journal-title":"Future Med Chem"},{"key":"B95","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/j.det.2015.05.010","article-title":"Histone deacetylase inhibitors for cutaneous T-cell lymphoma","volume":"33","author":"Duvic","year":"2015","journal-title":"Dermatol Clin"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1002\/emmm.201302796","article-title":"Synergistic combination of valproic acid and oncolytic parvovirus H-1PV as a potential therapy against cervical and pancreatic carcinomas","volume":"5","author":"Li","year":"2013","journal-title":"EMBO Mol Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1038\/leu.2011.140","article-title":"TAL1\/SCL is downregulated upon histone deacetylase inhibition in T-cell acute lymphoblastic leukemia cells","volume":"25","author":"Cardoso","year":"2011","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00093\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T10:52:59Z","timestamp":1602067979000},"score":1,"resource":{"primary":{"URL":"http:\/\/journal.frontiersin.org\/article\/10.3389\/fonc.2017.00093\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5,12]]},"references-count":97,"alternative-id":["10.3389\/fonc.2017.00093"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2017.00093","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,5,12]]},"article-number":"93"}}